Estudos científicos, publicações e artigos sobre medicamentos oncológicos para o tratamento de pacientes.


Trabalhos ReceptaBio

Apresentações em Congressos

Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors. de Souza, et al.

Veja o poster

Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates. Gombos, et al.

Veja o poster

AGEN2034, a Novel anti-PD-1 Antibody that Combines Effectively With CTLA-4 Pathway Blockade to Enhance T Cell Activity. Chand, et al.

Veja o poster

Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models.

Veja o poster

Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR).

Smaletz O, Ismael G, Diz MDPE, Nascimento IL, Wiermann ALG, Cunha GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, dos Santos ML, Majumder I, Hoffman EW. Journal of Clinical Oncology 2017 35:15_suppl, e17039-e17039.

Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies. Wilky, et al.

Veja o poster